Adipose tissue-derived stem cells (ADSCs) isolated from adult tissue have pluripotent differentiation and self-renewal capability. The tissue source of ADSCs can be obtained in large quantities and with low risks, thus highlighting the advantages of ADSCs in clinical applications. Valproic acid (VPA) is a widely used antiepileptic drug, which has recently been reported to affect ADSC differentiation in mice and rats; however, few studies have been performed on dogs. We aimed to examine the in vitro effect of VPA on canine ADSCs. Three days of pretreatment with VPA decreased the proliferation of ADSCs in a dose-dependent manner; VPA concentrations of 4 mM and above inhibited the proliferation of ADSCs. In parallel, VPA increased p16 and p21 mRNA expression, suggesting that VPA attenuated the proliferative activity of ADSCs by activating p16 and p21. Furthermore, the effects of VPA on adipogenic, osteogenic or neurogenic differentiation were investigated morphologically. VPA pretreatment markedly promoted neurogenic differentiation, but suppressed the accumulation of lipid droplets and calcium depositions. These modifications of ADSCs by VPA were associated with a particular gene expression profile, viz., an increase in neuronal markers, that is, NSE, TUBB3 and MAP2, a decrease in the adipogenic marker, LPL, but no changes in osteogenic markers, as estimated by reverse transcription-PCR analysis. These results suggested that VPA is a specific inducer of neurogenic differentiation of canine ADSCs and is a useful tool for studying the interaction between chromatin structure and cell fate determination.
Adipose tissue-derived stem cells (ADSCs) isolated from adult tissue have pluripotent differentiation and self-renewal capability. The tissue source of ADSCs can be obtained in large quantities and with low risks, thus highlighting the advantages of ADSCs in clinical applications. Valproic acid (VPA) is a widely used antiepileptic drug, which has recently been reported to affect ADSC differentiation in mice and rats; however, few studies have been performed on dogs. We aimed to examine the in vitro effect of VPA on canine ADSCs. Three days of pretreatment with VPA decreased the proliferation of ADSCs in a dose-dependent manner; VPA concentrations of 4 mM and above inhibited the proliferation of ADSCs. In parallel, VPA increased p16 and p21 mRNA expression, suggesting that VPA attenuated the proliferative activity of ADSCs by activating p16 and p21. Furthermore, the effects of VPA on adipogenic, osteogenic or neurogenic differentiation were investigated morphologically. VPA pretreatment markedly promoted neurogenic differentiation, but suppressed the accumulation of lipid droplets and calcium depositions. These modifications of ADSCs by VPA were associated with a particular gene expression profile, viz., an increase in neuronal markers, that is, NSE, TUBB3 and MAP2, a decrease in the adipogenic marker, LPL, but no changes in osteogenic markers, as estimated by reverse transcription-PCR analysis. These results suggested that VPA is a specific inducer of neurogenic differentiation of canine ADSCs and is a useful tool for studying the interaction between chromatin structure and cell fate determination.
Spinal cord injury (SCI) often occurs in dogs, due to motor vehicle accidents or
intervertebral disease (IVDD). Most caninepatients suffer from sustained incontinence and
loss of walking ability, and the prognosis of severe SCI cases is poor. Unfortunately, no
effective drug or surgical therapy has been established for severe SCI cases, and there is a
need for new therapeutic approaches. One possibility is stem cell transplantation therapy,
which is used as a radical cure treatment for refractory SCI [2, 14, 25, 26].Adipose tissue-derived stem cells (ADSCs) are isolated from the stromal vascular fraction of
adipose tissues [8, 24, 39]. ADSCs, similar to pluripotent adult
mesenchymal stem cells, can differentiate into mesenchymal lineage cells, such as adipocytes,
osteocytes, chondrocytes and myocytes [36, 38]. ADSCs have characteristics similar to those of bone
marrow-derived mesenchymal stem cells (BMSCs), including gene expression and differentiation
potential [1, 3,
5, 17, 19, 22, 33, 35, 37, 39]. Unlike
BMSCs, however, the tissue source of ADSCs can be obtained in large quantities and with low
risks [11]. Therefore, it is reasonable that ADSCs will
be the preferred adult stem cells for future clinical applications [24]. Moreover, the dog has been found to be a good animal model of human
disease [32], and thus, the study of canine ADSCs is
particularly useful. Stem cells derived from bone marrow and from olfactory ensheathing glia
(OEG) have been studied for spinal cord regenerative therapy in dogs [6, 14, 16, 25, 26, 31]. However, only a few studies
have been performed on the differentiation of canine ADSCs, except for a comparative study
showing that BMSCs and ADSCs could be differentiated into neurospheres and neuron-like cells
in dogs [2].Valproic acid (VPA), a widely used antiepileptic and anticonvulsant drug, is an inhibitor of
class 1 histone deacetylases (HDACs) [7, 27]. Histone acetylation correlates with gene activation
[12, 13], and
modification of histone N-terminal tails through acetylation or deacetylation can alter the
interaction between histones and DNA, affecting the regulation of gene expression [9, 12, 13, 18, 34]. Therefore, HDAC inhibitors have been a useful tool for
studying the association between chromatin modification and cell lineage specification. VPA
has been found to promote differentiation of hippocampal neural progenitors into neurons, but
inhibit their glial differentiation in adult rats [12].In the present study, we have investigated the effects of VPA on the proliferation and
differentiation of canine ADSCs isolated from subcutaneous adipose tissue in the inguinal
region.
MATERIALS AND METHODS
Animals: Subcutaneous adipose tissue was obtained from the inguinal region
of 8 healthy laboratory beagles (age, 1–2 years) (Kitayama Labes, Ina, Japan). All animals
were anesthetized with propofol, before tissue samples were obtained. After intubation,
anesthesia was maintained with isoflurane (2.0%) in oxygen. At the end of each experiment,
the animals were euthanized by additional doses of anesthesia (pentobarbital, 100 mg/kg).
The protocol of this study was approved by the Committee for Animal Experimentation at Azabu
University.Isolation and culture of canine ADSCs: Adipose tissue samples were
processed for ADSC isolation as described previously [23, 24] with a slight modification.
Briefly, the adipose tissue removed was extensively washed with sterile phosphate-buffered
saline (PBS) containing penicillin (100 U/ml) and streptomycin (0.25
µg/ml) in order to remove contaminating blood cells and
local anesthetics. The tissue was minced into small pieces and then incubated in a solution
containing 0.05% collagenase type IA (Sigma-Aldrich, St. Louis, MO, U.S.A.) at 37°C for 1 hr
with vigorous shaking. The top lipid layer was removed, and the remaining liquid portion was
centrifuged at 200 × g for 10 min. The pellet was resuspended in Dulbecco’s
modified Eagle’s medium (DMEM, Nissui, Tokyo, Japan) supplemented with 10% newborn bovine
serum (NBS, Invitrogen, Carlsbad, CA, U.S.A.) and spread in 100-mm collagen type I-coated
dishes (Iwaki, Tokyo, Japan) at a density of 1 × 106 cells per dish. Cells were
maintained in growth medium (DMEM supplemented with 10% NBS, penicillin [100
U/ml] and streptomycin [0.25 µg/ml]) at
37°C and 5% CO2. After 24 hr, the unattached cells were removed by washing with
PBS. Canine ADSCs from passages 1–3 were used, and no difference was observed in ADSCs
between these passages.Measurement of proliferation potential: The effects of VPA or valpromide
(VPM; Wako Pure Chemical Ind., Osaka, Japan), an analogue of VPA with no HDAC inhibitory
activity, on ADSC proliferation were measured using a 3-(4, 5-dimethyl-thiazol-2-yl)-2,
3-diphenyltetrazolium bromide (MTT) assay kit (Roche Applied Science, Basel, Switzerland)
according to the manufacturer’s instructions. Briefly, canine ADSCs were plated in 96-well
plates at a density of 1 × 104 per well and cultured in growth medium for 48 hr.
VPA or VPM (0–8 mM) was then added to the medium, and cultures were incubated for 3 days.
Subsequently, 10 µl of MTT stock solution was added, and the plates were
further incubated for 4 hr at 37°C. Diluted HCl (100 µl) was then added to
solubilize the formazan crystals, and the absorbance of each well at 570 nm
was measured with a microplate reader LS-PLATE manager 2004 (Wako Pure Chemical Ind.); the
average of measurements of 6 wells per sample has been presented.In vitro differentiation assay: In vitro assay of cell
differentiation into adipogenic, osteogenic and neurogenic lineages was performed as
described previously [4, 29, 39] with a slight
modification. Briefly, ADSCs were seeded into 35-mm dishes at a density of 1 ×
105 cells per dish. The cells were incubated on glass coverslips in growth
medium containing 4 mM VPA for 3 days and then transferred to adipogenic induction medium
(DMEM supplemented with 10% FBS, 1 µM dexamethasone, 10 µM
insulin and 0.5 mM isobutylmethylxanthine) or to osteogenic induction medium (DMEM
supplemented with 10% FBS, 0.1 µM dexamethasone, 50 µM
l-ascorbate-2-phosphte and 10 mM glycerophosphate) for 14 days [39] and then to neurogenic induction medium (DMEM supplemented with100
µM dibutyryl cyclic adenosine monophosphate and 125 µM
isobutylmethylxanthine) for 2 hr [23, 24]. Intracellular lipid accumulation, as an indicator of
adipogenic differentiation, was visualized by oil red O staining. Osteogenic differentiation
was confirmed by positive staining with alizarin red S, a specific marker for calcium
deposition. Neurogenic differentiation was assessed by immunofluorescence staining for
βIII-tubulin or neuron-specific enolase (NSE). Reagents for this induction medium were
purchased from Wako Pure Chemical Ind.Immunofluorescence staining: Immunocytochemical analyses of HDAC1,
acetylation of histone H3 (ace H3), βIII-tubulin and NSE were performed. ADSCs were
incubated in growth medium for 3 days as described above. Some cultures were processed for
neurogenic induction. At the end of incubation, the cells were fixed in PBS containing 3.7%
formaldehyde for 15 min at 4°C. After PBS washes, the cells were permeabilized with 0.2%
Triton X-100 for 10 min at room temperature. The cells were then incubated with an
anti-HDAC1 antibody (sc-7872, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.), an
anti-histone H3 (acetyl K9) antibody (Novus Biologicals, Littleton, CO, U.S.A.), an
anti-βIII-tubulin antibody (ab78078, Abcam, Cambridge, U.K.) or an anti-NSE antibody
(PA1-46203, Thermo Scientific, Billerica, MA, U.S.A.) for 1 hr at room temperature. After
further PBS washes, cells were incubated with secondary antibody (Cy3-conjugated goat
anti-rabbit IgG or FITC-conjugated goat anti-mouse IgG, Jackson ImmunoResearch, West Grove,
PA, U.S.A.) for 30 min at room temperature. The cells were then washed with PBS and
counterstained with 4′, 6-diamidino-2-phenyl-indole (DAPI) for nuclear staining before
fluorescence microscopic observation.Reverse transcription-PCR and real-time PCR: Total RNA was extracted using
ISOGEN (NIPPON GENE, Tokyo, Japan) and reverse-transcribed to single-strand cDNA using
oligo-dT primer and Superscript III reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. PCR was performed using Taq DNA polymerase
(KAPA Biosystems, Woburn, MA, U.S.A.) and using specific primers, and each cycle consisted
of the following steps: denaturation for 10 sec at 98°C, annealing for 30 sec at 53–65°C and
a 30-sec elongation at 72°C (Table 1). Reaction products were electrophoresed on a 2.0% agarose gel and visualized
with ethidium bromide. Real-time PCR of the mRNAs for p16,
p21 and GAPDH was performed using an ABI PRISM 7500
Sequence Detection System (Applied Biosystems Japan, Tokyo, Japan) according to the
manufacturer’s instructions. Analysis of the results was carried out using ABI PRISM 7500
Dissociation Curve Software v 1.0 (Applied Biosystems Japan). The relative amount of mRNA
was normalized to that of GAPDH.
Table 1.
Primers used in RT-PCR and real-time PCR
Gene
Primer sequence (5′–3′)
Product length (bp)
p16
Forward
CGATCCAGGTCATGATGATGG
145
Reverse
ACCACCAGCGTGTCCAGGAA
p21
Forward
CATCCCTCATGGCAGCAAG
208
Reverse
AGGCAGGGAGACCTTGGACA
PPARγ2
Forward
ACACGATGCTGGCGTCCTTGATG
119
Reverse
TGGCTCCATGAAGTCACCAAAGG
FABP4
Forward
ATCAGTGTAAACGGGGATGTG
117
Reverse
GACTTTTCTGTCATCCGCAGTA
LPL
Forward
ACACATTCACAAGAGGGTCACC
134
Reverse
CTCTGCAATCACACGGATGGC
BMP2
Forward
CACTAACCACGCCATTGTTCA
163
Reverse
ACAACCCTCCACAACCATGTC
Dlx5
Forward
TGCTCTCCTACCTCGGCTTC
224
Reverse
TTGCCATTCACCATCCTCAC
COL1A1
Forward
GTAGACACCACCCTCAAGAGC
119
Reverse
TTCCAGTCGGAGTGGCACATC
NSE
Forward
GACCAACCCAAAGCGTATTGA
180
Reverse
GCAATGAACGTGTCCTCAGTC
TUBB3
Forward
AGCCAAGTTCTGGGAAGTCA
238
Reverse
CCCACTCTGACCAAAGATGAA
MAP2
Forward
AGAGGAGGTGTCTGCAAGGA
161
Reverse
GTGATGGAGGTGGAGAAGGA
NEFH
Forward
CTCAAAGGCACCAAGGACTC
244
Reverse
CAAAGCCAATCCGACATTCT
GFAP
Forward
AGATCCACGATGAGGAGGTG
104
Reverse
TCTTAGGGCTGCTGTGAGGT
GAPDH
Forward
GCTGAACGGGAAGCTCACTG
221
Reverse
CGTCGAAGGTGGAAGAGTGG
Statistical analysis: Results are expressed as the mean ± standard error.
Multiple comparisons were done with the Turkey–Kramer test after one-way analysis of
variance. A p-value<0.05 was considered statistically significant.
RESULTS
VPA induces acetylation of histone H3 and decreased cell proliferation: To
confirm the effect of VPA on HDAC1 and acetylation of histone H3, we examined the expression
of HDAC1 and acetylation of histone H3 by immunofluorescence staining. Minimal HDAC1 and
acetylation of histone H3 were observed in the control ADSCs. VPA flattened the morphology
of ADSCs and increased the expression of HDAC1 and the acetylation of histone H3 in ADSCs
after 3 days of treatment (Fig. 1A and 1B). In contrast, VPM did not cause any morphological changes or significant changes in
HDAC1 and histone H3 staining in ADSCs.
Fig. 1.
Effects of valproic acid on histone deacetylase 1 expression, histone H3 acetylation
and cell proliferation. Canine adipose tissue-derived stem cells (ADSCs) were treated
with valproic acid (VPA) or valpromide (VPM). (A) ADSCs were then processed for
immunofluorescence staining with an anti-histone deacetylase 1 (HDAC1) or an
anti-histone H3 (acetyl K9) antibody and a secondary antibody (Cy3-conjugated goat
anti-rabbit IgG). Red fluorescence indicates positive staining for HDAC1 (A) and
acetylation of histone H3 (B). Scale bar, 50 µm. (C) Cell
proliferation was measured by MTT assay and expressed as percentage of the negative
control (DMSO). Data represent the means ± S.E. (% of control) of 4 independent
experiments; each measurement was the average for 6 wells.
*P<0.05, significant difference among the indicated groups.
Effects of valproic acid on histone deacetylase 1 expression, histone H3 acetylation
and cell proliferation. Canineadipose tissue-derived stem cells (ADSCs) were treated
with valproic acid (VPA) or valpromide (VPM). (A) ADSCs were then processed for
immunofluorescence staining with an anti-histone deacetylase 1 (HDAC1) or an
anti-histone H3 (acetyl K9) antibody and a secondary antibody (Cy3-conjugated goat
anti-rabbit IgG). Red fluorescence indicates positive staining for HDAC1 (A) and
acetylation of histone H3 (B). Scale bar, 50 µm. (C) Cell
proliferation was measured by MTT assay and expressed as percentage of the negative
control (DMSO). Data represent the means ± S.E. (% of control) of 4 independent
experiments; each measurement was the average for 6 wells.
*P<0.05, significant difference among the indicated groups.Moreover, VPA treatment significantly decreased the proliferation of ADSCs in a
dose-dependent manner: about 20% (2 mM VPA), 40% (4 mM VPA) and 80% (8 mM VPA) of the
control group (Fig. 1C). However, VPM treatment
did not substantially affect ADSC proliferation. No dead cells were observed in any
VPA-treated groups by phase-contrast microscopy.VPA induces upregulation of cyclin-dependent kinase inhibitors: To assess
the effect of VPA on the expression of cyclin-dependent kinase (CDK) inhibitors, we examined
the expression of these genes by real time-PCR. The expression levels of
p16 mRNA significantly increased in the ADSCs treated with 4 mM VPA (4.6
fold vs. control); however, p16 mRNA expression levels did not change in
the cells treated with 8 mM VPA (2.1 fold vs. control; Fig. 2A). p21 mRNA expression levels significantly increased in the cells
treated with 8 mM VPA (Fig. 2B). The expression
levels of p21 mRNA were approximately 2.6 fold (4 mM VPA) and 3.0 fold (8
mM VPA) of that of the control group.
Fig. 2.
Effects of valproic acid on cyclin-dependent kinase inhibitor expression. Adipose
tissue-derived stem cells (ADSCs) were treated with valproic acid (VPA) or valpromide
(VPM). Total RNA was extracted from ADSCs after 3 days of treatment with VPA (4 or 8
mM) or VPM (8 mM). The relative expression of the cyclin-dependent kinase (CDK)
inhibitors p16(A) and p21(B) was quantified by real
time-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as an internal standard. Data are the means ± S.E. of 4–7 independent experiments. a,
b: bars with different letters at the top differ significantly; a vs. b,
P<0.05.
Effects of valproic acid on cyclin-dependent kinase inhibitor expression. Adipose
tissue-derived stem cells (ADSCs) were treated with valproic acid (VPA) or valpromide
(VPM). Total RNA was extracted from ADSCs after 3 days of treatment with VPA (4 or 8
mM) or VPM (8 mM). The relative expression of the cyclin-dependent kinase (CDK)
inhibitors p16(A) and p21(B) was quantified by real
time-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as an internal standard. Data are the means ± S.E. of 4–7 independent experiments. a,
b: bars with different letters at the top differ significantly; a vs. b,
P<0.05.VPA suppresses adipogenic and osteogenic differentiation: To assess the
effect of VPA on the pluripotency of ADSCs, we investigated whether VPA treatment alters the
differentiation of ADSCs into adipogenic and osteogenic lineages using an in
vitro differentiation assay. Oil red O staining revealed that ADSCs that
differentiated into the adipogenic lineage accumulated lipid droplets in the cytosol, as
compared to undifferentiated cells, which did not accumulate lipid droplets (Fig. 3A). VPA pretreatment followed by adipogenic induction significantly suppressed the
accumulation of lipid droplets. RT-PCR analysis showed that the mRNA expression levels of
adipogenic markers, peroxisome proliferator-activated receptor γ2 (PPARγ2),
fatty acid binding protein 4 (FABP4) and lipoprotein lipase
(LPL) were elevated by adipogenic induction (Fig. 3B). On the other hand, VPA pretreatment followed by adipogenic
induction significantly reduced the LPL mRNA expression level, in parallel
with the decreased accumulation of lipid droplets. Alizarin red S staining revealed that
ADSCs differentiated into osteogenic lineage cells with accumulated calcium deposition, as
compared with the undifferentiated cells, which demonstrated no calcium deposition (Fig. 4). VPA pretreatment followed by osteogenic induction significantly reduced calcium
deposition (Fig. 4A). mRNA expression levels of
osteogenic markers, viz., bone morphogenetic protein 2 (BMP2) and
distal-less homeobox 5 (DLX5), were also elevated by osteogenic induction,
but were not significantly affected by VPA pretreatment (Fig. 4B).
Fig. 3.
Valproic acid suppresses accumulation of lipid droplets. Adipose tissue-derived stem
cells (ADSCs) were pretreated with valproic acid (VPA) for 3 days followed by
adipogenic induction for 14 days. (A) Adipogenic differentiation was visualized by oil
red O staining after 14 days of induction with adipogenic medium. Arrowheads show
cells that accumulated lipid droplets. Scale bar, 50 µm. (B) RT-PCR
analysis of adipogenic markers, PPARγ2, FABP4 and
LPL, was performed using total RNA extracted from ADSCs after 14
days of adipogenic induction. AIM, adipogenic induction medium.
Fig. 4.
Valproic acid suppresses calcium deposition. Adipose tissue-derived stem cells
(ADSCs) were pretreated with valproic acid (VPA) for 3 days followed by osteogenic
induction for 14 days. (A) Osteogenic differentiation was evaluated by alizarin red S
staining after 14 days of induction with osteogenic medium. Arrowheads show cells that
accumulated calcium in the cytosol. Scale bar, 200 µm. (B) RT-PCR
analysis of osteogenic markers, BMP2, Dlx5 and
COL1A1, was performed using total RNA extracted from ADSCs after 14
days of osteogenic induction. OIM, osteogenic induction medium.
Valproic acid suppresses accumulation of lipid droplets. Adipose tissue-derived stem
cells (ADSCs) were pretreated with valproic acid (VPA) for 3 days followed by
adipogenic induction for 14 days. (A) Adipogenic differentiation was visualized by oil
red O staining after 14 days of induction with adipogenic medium. Arrowheads show
cells that accumulated lipid droplets. Scale bar, 50 µm. (B) RT-PCR
analysis of adipogenic markers, PPARγ2, FABP4 and
LPL, was performed using total RNA extracted from ADSCs after 14
days of adipogenic induction. AIM, adipogenic induction medium.Valproic acid suppresses calcium deposition. Adipose tissue-derived stem cells
(ADSCs) were pretreated with valproic acid (VPA) for 3 days followed by osteogenic
induction for 14 days. (A) Osteogenic differentiation was evaluated by alizarin red S
staining after 14 days of induction with osteogenic medium. Arrowheads show cells that
accumulated calcium in the cytosol. Scale bar, 200 µm. (B) RT-PCR
analysis of osteogenic markers, BMP2, Dlx5 and
COL1A1, was performed using total RNA extracted from ADSCs after 14
days of osteogenic induction. OIM, osteogenic induction medium.VPA promotes neurogenic differentiation: We further examined the effect of
VPA on the neurogenic lineage induction of ADSCs. βIII-tubulin immunofluorescence staining
revealed that ADSCs that differentiated into neurogenic cells had typical neuron-like cell
protrusions and higher βIII-tubulin levels than undifferentiated cells.
βIII-tubulin-positive cells also stained for NSE. VPA pretreatment followed by neurogenic
induction significantly enhanced the level of βIII-tubulin-positive cells with approximately
90% of ADSCs showing βIII-tubulin expression (Fig.
5A).
Fig. 5.
Valproic acid promotes neurogenic differentiation. Adipose tissue-derived stem cells
(ADSCs) were pretreated with valproic acid (VPA) for 3 days followed by neurogenic
induction. (A) Neurogenic differentiation was assessed by immunofluorescence staining
using an anti-βIII-tubulin antibody and a secondary antibody (FITC-conjugated goat
anti-mouse IgG) after 2 hr of induction with neurogenic medium. Arrowheads show cells
that expressed βIII-tubulin. Scale bar, 50 µm. (B) RT-PCR analysis of
the neurogenic markers, NSE, TUBB3,
MAP2 and NEFH and the glial marker,
GFAP, was performed using total RNA extracted from ADSCs after 2 hr
of neurogenic induction. NIM, neurogenic induction medium.
Valproic acid promotes neurogenic differentiation. Adipose tissue-derived stem cells
(ADSCs) were pretreated with valproic acid (VPA) for 3 days followed by neurogenic
induction. (A) Neurogenic differentiation was assessed by immunofluorescence staining
using an anti-βIII-tubulin antibody and a secondary antibody (FITC-conjugated goat
anti-mouse IgG) after 2 hr of induction with neurogenic medium. Arrowheads show cells
that expressed βIII-tubulin. Scale bar, 50 µm. (B) RT-PCR analysis of
the neurogenic markers, NSE, TUBB3,
MAP2 and NEFH and the glial marker,
GFAP, was performed using total RNA extracted from ADSCs after 2 hr
of neurogenic induction. NIM, neurogenic induction medium.mRNA levels of neurogenic markers, viz., NSE, TUBB3 and
microtubule-associated protein 2 (MAP2), were also elevated by neurogenic
induction, but mRNA expression of the glial cell marker, GFAP, was not
observed in any groups (Fig. 5B). Pretreatment
with VPA followed by neurogenic induction increased the expression of NSE,
TUBB3 and MAP2 and of neurofilament heavy polypeptide
(NEFH), as compared to that in the neurogenic induction group. VPA
pretreatment increased the number of βIII-tubulin-positive cells, even without neurogenic
induction. Furthermore, VPA elevated the mRNA expression levels of neurogenic markers in
ADSCs with and without neurogenic induction.
DISCUSSION
Here, we demonstrated that VPA flattened the morphology of canine ADSCs and markedly
induced their expression of HDAC1 and acetylation of histone H3. In contrast, VPM, an
analogue of VPA with no HDAC inhibitory activity, did not cause any morphological changes
and had no significant effects on HDAC1 and histone H3, indicating that the H3 acetylation
was increased by VPA. These observations support the findings of Lee et al.
[20]. Thus, our results clearly indicated that VPA
induced H3 acetylation by reducing HDAC1 activity in canine ADSCs.VPA, but not VPM, induced a significant and dose-dependent decrease in the proliferation of
ADSCs, suggesting that VPA suppresses ADSC proliferation through acetylation of histone H3.
p21 and p16, well-known CDK inhibitors, regulate cell cycle arrest. VPA induces expression
of these CDK inhibitors in human ADSCs and mesenchymal stem cells [20, 30]. We found that VPA
significantly induced mRNA expression levels of p16 at 4 mM and of
p21 at 8 mM without inducing cell death. p21 is also a
well-known HDAC-inhibitor responsive gene that is upregulated by hyperacetylation of
histones H3 and H4 [10, 20, 28]. In addition, using
immunofluorescence, we showed that H3 acetylation was markedly increased by VPA and that
p21 mRNA was significantly increased by 8 mM VPA; thus, cell viability
was further reduced by 8 mM VPA treatment, again supporting the findings of Lee et
al. [20] who reported that VPA causes cell
cycle arrest through increased p21 expression in the absence of
p16 mRNA expression in human ADSCs. Therefore, the inhibitory effect of
VPA on proliferation of canine ADSCs was due to cell cycle arrest, although the underlying
mechanism needs to be further examined.Furthermore, VPA promoted differentiation of approximately 90% of ADSCs into a neuronal
cell lineage after 3 days of treatment. The differentiated cells have neuron-like morphology
and significantly expressed βIII-tubulin protein. Pretreatment with VPA followed by
neurogenic induction also promoted mRNA expression of the neuronal markers
NSE, TUBB3, MAP2 and
NEFH as compared to the pretreatment without VPA, suggesting that
promotional effects of VPA on neuronal differentiation of ADSCs were induced by upregulation
of these genes. Previous reports have shown that VPA promotes differentiation of neural stem
cells into neurons in adult rats [12, 15]. To our knowledge, the present study is the first
report that VPA promotes neuronal differentiation of ADSCs.Interestingly, VPA pretreatment in the absence of neurogenic induction caused moderate
differentiation into neuron-like cells and also increased mRNA expression levels of
neurogenic markers in ADSCs. Thus, our data indicated that VPA could induce neurogenic
differentiation in the absence of neurogenic induction. We also demonstrated that VPA
increased the acetylation of histone H3 that has been correlated with gene activation [12, 13]; thus, VPA
caused gene expression in part through H3 acetylation. In addition, we showed that the
neuron-like differentiated cells all stained positively for βIII-tubulin. Using NG108-15
cells, Liu et al. [21] recently
reported that neuronal differentiation could modulate gene transcription, translation and
post-translational modulation of Ca2+ channels to change the Ca2+ ion
currents; our results suggested that neuronal differentiation could modulate
TUBB3 transcription and translation. In the present study, VPA promoted
ADSCs differentiation into neuronal cells in the absence of neurogenic induction factors and
induced acetylation of histone H3, indicating that VPA is a useful tool for studying the
interaction between chromatin structure and cell fate determination. Further studies are
needed to examine the molecular mechanism underlying the neurogenic differentiation induced
by VPA using canine ADSCs.In contrast, VPA suppressed the late stage of differentiation into adipogenic and
osteogenic lineage cells. Two of the 3 adipogenic marker genes examined showed no reduction
after VPA pretreatment; however, lipid accumulation appeared to be suppressed, suggesting
that the VPA inhibits accumulation of lipid droplets rather than an inhibiting the whole
adipogenic differentiation process.Similarly, osteogenic marker genes showed no changes after VPA treatment, but accumulation
of calcium deposition by osteogenic induction was significantly reduced, suggesting that VPA
inhibits calcium deposition rather than inhibiting the osteogenic differentiation process as
a whole. The mechanism underlying the differential effects of VPA on the pluripotent
capacity of ADSCs remains unclear. A previous report has shown that VPA decreases adipogenic
and neurogenic differentiation, but increases osteogenic differentiation in human ADSCs
[20]. The reason for VPA acting as a stimulator for
differentiation of canine ADSCs and as a suppressor for that of human ADSCs is not
immediately clear. Therefore, chromatin structure and cell fate determination need to be
further examined in relation to the pluripotency of ADSCs, including this difference between
humans and dogs.In conclusion, pretreatment with VPA dose-dependently decreased proliferation of canine
ADSCs. In parallel with its inhibitory effects, VPA increased p16 and
p21 mRNA expression, implying induction of cell cycle arrest through
activation of p16 and p21. In addition, pretreatment with VPA followed by adipogenic,
osteogenic or neurogenic induction markedly promoted in vitro neurogenic
differentiation, but suppressed accumulation of lipid droplets and calcium deposition. These
in vitro modifications of ADSCs by pretreatment with VPA were associated
with changes in expression of relevant markers. These results suggested that VPA is a
specific inducer of neurogenic differentiation of canine ADSCs and is a useful tool for
studying the interaction between chromatin structure and cell fate determination.
Authors: Tamara Salam Housman; Naomi Lawrence; Beverly G Mellen; Mary Noel George; James San Filippo; K Andrew Cerveny; Mario DeMarco; Steven R Feldman; Alan B Fleischer Journal: Dermatol Surg Date: 2002-11 Impact factor: 3.398
Authors: M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel Journal: EMBO J Date: 2001-12-17 Impact factor: 11.598